JB
OVID icon

Julian Baker’s Ovid Therapeutics OVID Stock Holding History

Julian Baker’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-955,690
Closed -$2.21M – 130
2020
Q4 		$2.21M Buy
955,690
+364,929
+62% +$1.7M 0.01% 109
2020
Q3 		$3.39M Buy
590,761
+132,508
+29% +$887K 0.01% 89
2020
Q2 		$3.38M Buy
458,253
+388,782
+560% +$1.82M 0.01% 85
2020
Q1 		$207K Buy
+69,471
New +$234K ﹤0.01% 109
2018
Q4 		– Sell
-222,139
Closed -$1.26M – 95
2018
Q3 		$1.26M Sell
222,139
-25,594
-10% -$194K 0.01% 90
2018
Q2 		$1.93M Hold
247,733
– – 0.01% 95
2018
Q1 		$1.75M Sell
247,733
-85,600
-26% -$693K 0.01% 93
2017
Q4 		$3.29M Hold
333,333
– – 0.03% 87
2017
Q3 		$2.86M Hold
333,333
– – 0.02% 89
2017
Q2 		$3.5M Buy
+333,333
New +$4.35M 0.03% 72

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Julian Baker's OVID Position: Q1 2021 in Review

Julian Baker sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 955,690 shares — an estimated $2.21M sold.

Julian Baker first reported a position in OVID in Q2 2017 and held it in 10 quarters. The position peaked at $3.5M in Q2 2017. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

  • Julian Baker reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Julian Baker sold 955,690 Ovid Therapeutics shares in Q1 2021, an estimated $2.21M.
  • Julian Baker first reported a position in Ovid Therapeutics in Q2 2017 and held it in 10 quarters.
  • Julian Baker's Ovid Therapeutics position peaked at $3.5M in Q2 2017.
  • 88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.